In:
Cancer, Wiley, Vol. 125, No. 18 ( 2019-09-15), p. 3208-3218
Abstract:
In the randomized, open‐label, phase 3 CheckMate 141 trial in patients with recurrent/metastatic squamous cell carcinoma of the head and neck after platinum therapy, patients with a stable performance status and the potential for clinical benefit were permitted to receive treatment beyond first Response Evaluation Criteria in Solid Tumors–defined progression (TBP) with nivolumab; tumor burden reduction was noted in a proportion of these patients. Additional research is warranted to identify factors predictive of benefit with TBP in this population.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v125.18
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1